Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
drugs
3
×
life sciences
national blog main
onpattro
3
×
patisiran
akcea therapeutics
alnylam pharmaceuticals
boston
clinical trials
fda
inotersen
national top stories
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
aminolevulinic acid
anylam pharmaceuticals
cardiomyopathy
european medicines agency
givosiran
harvard pilgrim health care
hereditary transthyretin amyloidosis
institute for clinical and economic review
neuropathy
new york
paul matteis
rna interference
stifel financial
tegsedi
transthyretin amyloidosis
What
alnylam
3
×
drug
fda
ago
interference
medicine
rna
rnai
akcea
amyloidosis
approval
approved
approves
attr
available
battle
cells
debilitating
disease
ema
employ
europe
follows
gene
genetic
harmful
hits
indicated
make
medicines
method
mute
nod
oks
patients
pfizer
pharmaceuticals
protein
quick
rare
Language
Current search:
alnylam
×
drugs
×
onpattro
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug